Understanding Intended Purpose in EU MDR & IVDR: Key Implications for Medical Device Manufacturers

REPHINE SPEECH MARKS OPEN MEDICALDEVICES

The intended purpose is a fundamental regulatory concept that shapes the classification, safety, and market approval of medical and in vitro diagnostic devices.

REPHINE SPEECH MARKS CLOSE MEDICALDEVICES

About this Guide

This guide provides a comprehensive overview of the “intended purpose” as defined in Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR).

It explores the regulatory definition, its key components, and its critical role in ensuring compliance, patient safety, and successful market entry for medical devices and in vitro diagnostic (IVD) devices in the European Union.

 

Why Is Intended Purpose Important?

The intended purpose is a cornerstone of the MDR and IVDR frameworks, impacting:

  • Device Risk Classification: Determines the level of regulatory scrutiny and conformity assessment procedures.
  • Clinical Evaluation & Performance Evaluation: Defines the scope of clinical investigations and performance studies required to demonstrate safety and efficacy.
  • Post-Market Surveillance (PMS): Guides ongoing monitoring and reporting of adverse events to ensure real-world safety.


Gain a deeper understanding of the intended purpose and its implications for your medical or IVD devices.

Download the guide now to ensure your documentation is audit-ready and fully aligned with EU regulations.

Hero Image Intended Purpose Guide MedTech

Key Topics Covered

  1. Definition of Intended Purpose: Learn how the MDR and IVDR define intended purpose and its importance in regulatory compliance.

  2. Linked Concepts: Explore related terms such as indications for use, target populations, intended users, and use environment.

  3. Intended Purpose as the Cornerstone of Technical Documentation: Understand how intended purpose influences risk classification, clinical evaluation, and post-market surveillance.

  4. Conclusion: Discover why clearly defining and substantiating intended purpose is critical for regulatory success and patient safety.

View our other resources and company news

GMP Raising the bar Blog series Header image May 25 Article

Effective QMS Management Post-Go-Live: Strategies for Governance, Releases, and Continuous Improvement

After QMS go live, compliance and performance depend on strong governance, structured release management and continuous improvement. Learn how to sustain control, adoption and long ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan Case Study

GMP Consultancy for a New Manufacturing Plant

With only a small team and a highly automated process, this biotech company needed to achieve EU GMP compliance fast. This case study shows how ...
Read More
ICH E6 Guide Header Image (1500 x 844 px) Article

Why Quality Can No Longer Live in Silos

Discover why siloed quality management is no longer sustainable in life sciences. Learn how integrating audits, advisory services and digital quality systems supports continuous GxP ...
Read More
QMS IMP Header image Blog case study May 25 Article

Why Most QMS Implementations Fail to Deliver Long-Term Value

Implementing a QMS is more than deploying software. Learn why most QMS implementations fall short, and what successful life sciences teams do differently to achieve ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan Case Study

Driving Global QMS Harmonisation for a Pharmaceutical Company

This case study outlines how Rephine helped a global pharmaceutical group implement and validate a harmonised Quality Management System across more than seventy sites. It ...
Read More
CSV Blog

IT Quality Assurance in Regulated Life Sciences: Key Insights

IT Quality Assurance is pivotal in regulated life sciences. From CSV and data integrity to change control and audit readiness, discover how IT QA ensures ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan General

Practical compliance and inspection readiness for UK pharmaceutical quality systems

Explore how UK pharmaceutical and biotech organisations can stay prepared for MHRA, EMA and FDA inspections. This session provides expert guidance on inspection trends, compliance ...
Read More
BANNER Practical Guide to Post Market Surveillance PMS under EU MDR IVDR CSV

Practical Guide to the EMA’s Draft EU GMP Revisions

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
BANNER Practical Guide to Post Market Surveillance PMS under EU MDR IVDR Guide

Practical Guide to Post-Market Surveillance (PMS) under EU MDR/IVDR

The EU’s new Product Liability Directive (2024/2853) changes who can be held liable and what damages can be claimed. From software and data loss to ...
Read More
Contact Us

Strengthen Your Assurance Journey

GMP Chapter 22 Adapting to Hybrid Documentation Standards